非小细胞肺癌化疗疗效预测基因ERCC1的研究进展

ERCC1:A new predictive genomic marker for chemotherapy of non-small cell lung cancer

非小细胞肺癌(non-small cell lung cancer,NSCLC)是现今世界范围内最常见的恶性肿瘤之一。手术及化疗是其治疗的主要方法,研究和确定临床上NSCLC化疗敏感性预测的靶向分子和指标将有利于NSCLC患者的个体化治疗。该文就核苷酸切除修复交叉互补组1(excision repair cross complementation group 1,ERCC1)基因作为NSCLC化疗疗效预测指标的研究现状作一综述。

Non-small cell lung cancer （NSCLC） is one of the most common malignant tumors worldwide. Surgery and chemotherapy are the main methods in therapy of NSCLC. The study and identification of predictive tar- geting molecules and markers of chemosensitivity of NSCLC will be beneficial to customized treatment of NSCLC pa- tients. This article will review the research status about excision repair cross complementation group 1 （ ERCC1 ） as a predictive marker for chemotherapy of NSCLC.